Valuation dashboard for West Pharmaceutical Services, Inc. (WST) with P/E 53.28, P/B 9.88, EV/EBITDA 30.16 and dividend yield 0.21%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products.
Analysis Summary
West Pharmaceutical Services, Inc. reported revenue of $3.07B in the most recent fiscal year, growing at a 5-year CAGR of 7.4%. Net income reached $493.7M, with a 7.4% 5-year CAGR.
Trailing-twelve-month margins: gross margin 37.6%, operating margin 23.0%, net margin 18.8%.
At $416.67 (closing price, October 29, 2026), WST trades at a P/E of 53.28 and an ROE of 21.08%. Market capitalisation stands at $29.3B, placing it among large-cap names.
Balance sheet quality for WST: current ratio of 3.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 53.28 |
| Price / Book | 9.88 |
| EV / EBITDA | 30.16 |
| Dividend Yield | 0.21% |
Valuation Models
| DCF Fair Value | $89.75 |
| vs Current Price | -78.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| WST | West Pharmaceutical Services, Inc. | $29.3B | 53.28 | 9.88 | 21.1% |
| ICUI | ICU Medical, Inc. | $4.2B | 141.20 | 1.96 | 1.4% |
| ATR | AptarGroup, Inc. | $8.3B | 23.62 | 295.87 | 13.4% |
| STVN | Stevanato Group S.p.A. | $5.5B | 37.86 | 3.20 | 8.9% |
| ISRG | Intuitive Surgical, Inc. | $158.5B | 53.87 | 9.70 | 17.0% |
| 0R29.L | Intuitive Surgical, Inc. | $150.3B | 54.04 | 9.87 | 17.0% |
| 0R19.L | Becton, Dickinson and Company | $54.2B | 59.91 | 2.24 | 3.8% |
| BDX | Becton, Dickinson and Company | $54.0B | 59.74 | 2.20 | 3.8% |
Price
| Price | $416.67 (closing price, October 29, 2026) |
| Market Cap | $29.3B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 21.08% |
| Return on Invested Capital | 17.89% |
| Return on Assets | 15.73% |
| Gross Margin | 37.59% |
| Operating Margin | 22.97% |
| Net Margin | 18.81% |
Related companies: ICUI · ATR · STVN · ISRG · 0R29.L · 0R19.L · BDX · RMD
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of WST: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks